Regulus Therapeutics
RGLS
#7313
Rank
ยฃ0.42 B
Marketcap
ยฃ6.08
Share price
0.00%
Change (1 day)
425.76%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -ยฃ36.82 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -ยฃ34.45 Million a decrease over its 2023 earnings that were of -ยฃ21.95 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -ยฃ36.82 Million6.87%
2024 -ยฃ34.45 Million56.97%
2023 -ยฃ21.95 Million6.51%
2022 -ยฃ20.61 Million2.53%
2021 -ยฃ20.1 Million93.59%
2020 -ยฃ10.39 Million-15.41%
2019 -ยฃ12.28 Million-64.46%
2018 -ยฃ34.53 Million-33.26%
2017 -ยฃ51.74 Million-13.98%
2016 -ยฃ60.15 Million44.77%
2015 -ยฃ41.55 Million-1.63%
2014 -ยฃ42.24 Million203.6%
2013 -ยฃ13.92 Million8.65%
2012 -ยฃ12.81 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
ยฃ5.33 B-15,196.86%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
ยฃ0.75 B-2,232.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ8.88 B-25,211.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ10.68 B-30,317.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
ยฃ5.88 B-16,734.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-ยฃ82.26 Million 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-ยฃ87.73 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
ยฃ0.83 B-2,471.21%๐Ÿ‡บ๐Ÿ‡ธ USA